Loblaw Companies: The Valuation Needs To Go On Sale

Loblaw’s Q2 2026 results were solid: retail revenue rose 4.1% YoY and net earnings increased 5.2%, supported by strong same-store sales across discount and pharmacy. However, the stock trades at a 2026 forward P/E of 23.61x, above its five-year average, suggesting valuation is currently rich. Net effect is modestly positive fundamentals offset by concerns about price/takeout risk.

Analysis

Loblaw’s scale is still the core moat, but in Canadian grocery that moat often shows up as industry-wide margin pressure rather than an easy route to outsized profit growth. The company’s strength in discount and pharmacy should keep traffic resilient, yet it also signals a consumer trading-down backdrop that caps basket expansion and keeps the competitive response from Metro (MRU.TO), Empire (EMP.A.TO), Walmart Canada, and Costco disciplined on price. That dynamic is usually better for share gains than for multiple expansion.

The market problem is the entry point: a high-teens/low-20s earnings grower being valued like a compounder leaves little room for disappointment. If rates stay elevated, defensive retail names with bond-like characteristics tend to re-rate lower even when operations are fine; a 1-2 turn multiple reset would wipe out a full year of mid-single-digit EPS growth. The next 1-3 months are mostly about guidance quality and whether cost savings are truly structural versus just offsetting inflation.

Contrarian case: the market may be underestimating the durability of Loblaw’s procurement advantage and pharmacy mix, which can sustain traffic better than pure grocery peers. The bigger risk to that bull case is normalization—if food inflation cools or price gaps narrow, reported growth can decelerate fast because a lot of the current resilience is nominal rather than unit-driven. Watch private-label share, pharmacy same-store growth, and any sign that competitors are matching promotions more aggressively; those would be the first falsifiers.

Key Decisions for Investors

• Underweight/short L.TO on strength; target a 5-10% drawdown from multiple compression if the stock continues to trade above ~23x forward earnings without an upward revision to long-term margin assumptions.
• Pair trade: short L.TO vs long MRU.TO for 1-3 months. The thesis is that Loblaw’s premium valuation is harder to defend than a higher-quality but cheaper peer if sector multiples compress.
• If options liquidity allows, buy a 6-9 month L.TO put spread to express valuation re-rating risk with defined downside; use it only if the next print fails to show meaningful operating leverage.
• Set an alert if forward P/E stays above 22x after the next earnings cycle while same-store sales decelerate; that would be the clearest trigger to add to the short.